Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Study of Bulevirtide in Chronic Hepatitis D
2023-504414-29-00Phase 4Authorised
- Sponsor
- Karolinska University Hospital
- Start
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bulevirtide in hepatitis D (HDV) and hepatitis B (HBV), sponsored by Karolinska University Hospital. Planned start May 2023; status: authorised.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)hepatitis B (HBV)
Beyond the preview
Go deeper on 2023-504414-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504414-29-00.